Myelofibrosis with myeloid metaplasia: Disease overview and non-transplant treatment options

Ruben Mesa, Giovanni Barosi, Francisco Cervantes, John T. Reilly, Ayalew Tefferi

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Myelofibrosis with myeloid metaplasia (MMM) is currently classified as a classic (i.e. not yet molecularly defined) myeloproliferative disorder (MPD), along with essential thrombocythemia (ET) and polycythemia vera (PV). All three MPDs represent stem-cell-derived clonal myeloproliferation that, in the case of MMM, is accompanied by an intense bone marrow stromal reaction that includes collagen fibrosis, osteosclerosis, and angiogenesis. To date, both the molecular basis of the primary clonal process and the pathogenetic mechanisms that underlie the secondary histological changes remain elusive. Clinically, MMM is characterized by anemia, multi-organ extramedullary hematopoiesis that often involves the spleen and liver, constitutional symptoms, and premature death from either leukemic transformation or other disease complications. Current diagnosis is based on characteristic but not diagnostic bone marrow histological features. Modern therapy remains palliative but allogeneic stem cell transplantation might be curative to a selected group of patients. This chapter reviews both the old and the new therapy with regard to non-transplant treatment options for MMM.

Original languageEnglish (US)
Pages (from-to)495-517
Number of pages23
JournalBest Practice and Research: Clinical Haematology
Volume19
Issue number3
DOIs
StatePublished - Sep 1 2006
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Stem cells
Bone
Liver
Collagen
Bone Marrow
Osteosclerosis
Extramedullary Hematopoiesis
Essential Thrombocythemia
Myeloproliferative Disorders
Polycythemia Vera
Premature Mortality
Stem Cell Transplantation
Therapeutics
Palliative Care
Anemia
Fibrosis
Stem Cells
Spleen

Keywords

  • idiopathic myelofibrosis
  • myelofibrosis with myeloid metaplasia
  • myeloproliferative disorders
  • therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Clinical Biochemistry

Cite this

Myelofibrosis with myeloid metaplasia : Disease overview and non-transplant treatment options. / Mesa, Ruben; Barosi, Giovanni; Cervantes, Francisco; Reilly, John T.; Tefferi, Ayalew.

In: Best Practice and Research: Clinical Haematology, Vol. 19, No. 3, 01.09.2006, p. 495-517.

Research output: Contribution to journalReview article

Mesa, Ruben ; Barosi, Giovanni ; Cervantes, Francisco ; Reilly, John T. ; Tefferi, Ayalew. / Myelofibrosis with myeloid metaplasia : Disease overview and non-transplant treatment options. In: Best Practice and Research: Clinical Haematology. 2006 ; Vol. 19, No. 3. pp. 495-517.
@article{dff14cced70644c89e6276e294b8a543,
title = "Myelofibrosis with myeloid metaplasia: Disease overview and non-transplant treatment options",
abstract = "Myelofibrosis with myeloid metaplasia (MMM) is currently classified as a classic (i.e. not yet molecularly defined) myeloproliferative disorder (MPD), along with essential thrombocythemia (ET) and polycythemia vera (PV). All three MPDs represent stem-cell-derived clonal myeloproliferation that, in the case of MMM, is accompanied by an intense bone marrow stromal reaction that includes collagen fibrosis, osteosclerosis, and angiogenesis. To date, both the molecular basis of the primary clonal process and the pathogenetic mechanisms that underlie the secondary histological changes remain elusive. Clinically, MMM is characterized by anemia, multi-organ extramedullary hematopoiesis that often involves the spleen and liver, constitutional symptoms, and premature death from either leukemic transformation or other disease complications. Current diagnosis is based on characteristic but not diagnostic bone marrow histological features. Modern therapy remains palliative but allogeneic stem cell transplantation might be curative to a selected group of patients. This chapter reviews both the old and the new therapy with regard to non-transplant treatment options for MMM.",
keywords = "idiopathic myelofibrosis, myelofibrosis with myeloid metaplasia, myeloproliferative disorders, therapy",
author = "Ruben Mesa and Giovanni Barosi and Francisco Cervantes and Reilly, {John T.} and Ayalew Tefferi",
year = "2006",
month = "9",
day = "1",
doi = "10.1016/j.beha.2005.07.008",
language = "English (US)",
volume = "19",
pages = "495--517",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "3",

}

TY - JOUR

T1 - Myelofibrosis with myeloid metaplasia

T2 - Disease overview and non-transplant treatment options

AU - Mesa, Ruben

AU - Barosi, Giovanni

AU - Cervantes, Francisco

AU - Reilly, John T.

AU - Tefferi, Ayalew

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Myelofibrosis with myeloid metaplasia (MMM) is currently classified as a classic (i.e. not yet molecularly defined) myeloproliferative disorder (MPD), along with essential thrombocythemia (ET) and polycythemia vera (PV). All three MPDs represent stem-cell-derived clonal myeloproliferation that, in the case of MMM, is accompanied by an intense bone marrow stromal reaction that includes collagen fibrosis, osteosclerosis, and angiogenesis. To date, both the molecular basis of the primary clonal process and the pathogenetic mechanisms that underlie the secondary histological changes remain elusive. Clinically, MMM is characterized by anemia, multi-organ extramedullary hematopoiesis that often involves the spleen and liver, constitutional symptoms, and premature death from either leukemic transformation or other disease complications. Current diagnosis is based on characteristic but not diagnostic bone marrow histological features. Modern therapy remains palliative but allogeneic stem cell transplantation might be curative to a selected group of patients. This chapter reviews both the old and the new therapy with regard to non-transplant treatment options for MMM.

AB - Myelofibrosis with myeloid metaplasia (MMM) is currently classified as a classic (i.e. not yet molecularly defined) myeloproliferative disorder (MPD), along with essential thrombocythemia (ET) and polycythemia vera (PV). All three MPDs represent stem-cell-derived clonal myeloproliferation that, in the case of MMM, is accompanied by an intense bone marrow stromal reaction that includes collagen fibrosis, osteosclerosis, and angiogenesis. To date, both the molecular basis of the primary clonal process and the pathogenetic mechanisms that underlie the secondary histological changes remain elusive. Clinically, MMM is characterized by anemia, multi-organ extramedullary hematopoiesis that often involves the spleen and liver, constitutional symptoms, and premature death from either leukemic transformation or other disease complications. Current diagnosis is based on characteristic but not diagnostic bone marrow histological features. Modern therapy remains palliative but allogeneic stem cell transplantation might be curative to a selected group of patients. This chapter reviews both the old and the new therapy with regard to non-transplant treatment options for MMM.

KW - idiopathic myelofibrosis

KW - myelofibrosis with myeloid metaplasia

KW - myeloproliferative disorders

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=33744981848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744981848&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2005.07.008

DO - 10.1016/j.beha.2005.07.008

M3 - Review article

C2 - 16781486

AN - SCOPUS:33744981848

VL - 19

SP - 495

EP - 517

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 3

ER -